Prostate Cancer

Stereotactic body radiotherapy was not associated with any dose-limiting toxicities.

Both forms of therapy are considered standard of care in prostate cancer; however, some data suggest that proton therapy may offer a safer alternative without sacrificing efficacy.

The NanoTherm therapy system is being explored for the focal ablation of intermediate-risk prostate cancer.

The vaccine was examined in a trial of patients with metastatic castration-resistant prostate cancer who were not responding to available therapies.

The genomic assay did not increase use of active surveillance in a predominantly African-American population of men with favorable-risk prostate cancer.

Exploration of the novel combination continues after early-phase published data showed promising clinical activity.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

A phase 3 trial has already been launched to build on these early results with the combination of the PARP inhibitor and androgen receptor inhibitor.

Tumors exhibiting homozygous DNA damage response (DDR) alterations were more likely to respond to talazoparib than those with heterozygous DDR alterations.

Jason Zhu, MD, discusses factors he considers when choosing treatment for patients with lymph node–positive prostate cancer after prostatectomy.

Ward's analysis includes a discussion of adjuvant radiotherapy versus early salvage radiotherapy.

Using a blood or saliva sample, ProstateNow employs a 3-pronged approach for assessing risk.

“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer.

Leonard G. Gomella, MD, discusses questions that still need to be resolved with biomarkers for the diagnosis and management of patients with prostate cancer.

The trend persists even after adjusting for surgical volume and experience.

Scott T. Tagawa, MD, highlights pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent radium-223 in prostate cancer.

The European Commission is reviewing supporting data from the phase 3 ARCHES trial.

Dr. Leonard G. Gomella discusses emerging biomarkers and the use of MRI for the early detection of prostate cancer.

“This study represents the most comprehensive analysis to date of tumor mutation burden as a biomarker for response to immune checkpoint blockade,” according to lead study author Daniel J. McGrail, PhD.

Transperineal prostate biopsy was associated with a higher likelihood of upgrading to clinically significant prostate cancer versus transrectal prostate biopsy among men on active surveillance.

“The way I think about this test now is… more as a dichotomous score,” says Eric A. Klein, MD.

The targeted radioligand therapy 177Lu-PSMA-617 also improved progression-free survival when added to best standard of care (BSC) compared with BSC alone.

Scott T. Tagawa, MD, explained the latest developments with the radiopharmaceutical radium-223 at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.